https://pixabay.com/photos/hospital-infusion-hand-association-834157/
EHA2021: Longer-Term Data Presented on Yescarta for R/R Follicular Lymphoma
During the European Hematology Association (EHA)'s 26th Annual Meeting, taking place virtually, biopharmaceutical company Kite (part of Gilead) shared longer-term follow-up data on Yescarta (axicabtagene ciloleucel) for patients with relapsed…
Continue Reading
EHA2021: Longer-Term Data Presented on Yescarta for R/R Follicular Lymphoma
